Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Authors:
Open Access
- 1 August 2003
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 14 (8) , 1215-1221
Abstract
Background: Adjuvant systemic treatment for patients with isolated locoregional recurrence (ILRR) of breast cancer is based on a single reported randomized trial. The trial, conducted by the Swiss Group for Clinical Cancer Research, compared tamoxifen (TAM) with observation after complete excision of the ILRR and proper radiotherapy. We performed a definitive analysis of treatment outcome at >11 years of follow-up, after the majority of the patients had a subsequent event of interest. Patient and methods One hundred and sixty-seven patients with ‘good-risk’ characteristics of disease were randomized. ‘Good-risk’ was defined as estrogen receptor expression in the ILRR, or having a disease-free interval of >12 months and a recurrence consisting of three or less tumor nodules, each ≤3 cm in diameter. Seventy-nine percent of the patients were postmenopausal at randomization. Results: The median follow-up time of the surviving patients was 11.6 years. The median post ILRR disease-free survival (DFS) was 6.5 years with TAM and 2.7 years with observation (P = 0.053). The difference was mainly due to reduction of further local relapses (P = 0.011). In postmenopausal patients, TAM led to an increase of DFS from 33% to 61% (P = 0.006). In premenopausal women, 5-year DFS was 60%, independent of TAM medication. For the whole study population, the median post-recurrence overall survival (OS) was 11.2 and 11.5 years in the observation and the TAM group, respectively; premenopausal patients experienced a 5-year OS of 90% for observation compared with 67% for TAM (P = 0.175), while the respective figures for postmenopausal patients were both 75%. Conclusions: These definitive results confirmed that TAM significantly improves the post-recurrence DFS of patients after local treatment for ILRR. This beneficial effect does not translate into a detectable OS advantage.Keywords
This publication has 23 references indexed in Scilit:
- Prognostic and predictive factors in breast cancerCancer Treatment Reviews, 2001
- Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?The Lancet, 2000
- Role of Isolated Locoregional Recurrence of Breast Cancer: Results of Four Prospective StudiesJournal of Clinical Oncology, 2000
- Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancerEuropean Journal of Cancer, 1996
- Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic featuresInternational Journal of Cancer, 1995
- Tamoxifen in premenopausal patients with metastatic breast cancer: a review.Journal of Clinical Oncology, 1991
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomyCancer, 1986
- A Biometrics Invited Paper with Discussion. Some Aspects of Analysis of Covariance1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958